STOCK TITAN

T. Rowe Price discloses 4.9% Guardant Health (GH) holding in 13G/A

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. reported beneficial ownership of common stock of Guardant Health, Inc.. The firm held 6,514,828 shares of Guardant Health common stock, representing 4.9% of the class as of June 30, 2026.

T. Rowe Price reported sole voting power over 6,359,951 shares and sole dispositive power over 6,514,828 shares, with no shared voting or dispositive power. The filer expressly denied that this filing should be construed as an admission of beneficial ownership of these securities.

Positive

  • None.

Negative

  • None.
Beneficially owned shares 6,514,828 shares Common stock beneficially owned by T. Rowe Price Associates, Inc.
Percent of class 4.9% Percentage of Guardant Health common stock class held
Sole voting power 6,359,951 shares Shares for which T. Rowe Price can solely vote or direct the vote
Sole dispositive power 6,514,828 shares Shares for which T. Rowe Price can solely dispose or direct disposition
Shared voting power 0 shares No shared voting power reported
beneficial owner financial
"shall not be construed as an admission that Price Associates is the beneficial owner"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
Sole Voting Power financial
"Sole Voting Power 6,359,951.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Sole Dispositive Power financial
"Sole Dispositive Power 6,514,828.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Percent of class financial
"Percent of class: 4.9 %"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

What percentage of Guardant Health (GH) shares does T. Rowe Price Associates, Inc. report owning?

T. Rowe Price Associates, Inc. reports beneficial ownership of 4.9% of Guardant Health’s common stock. This corresponds to 6,514,828 shares of GH common stock as disclosed in the Schedule 13G/A amendment.

How many Guardant Health (GH) shares does T. Rowe Price Associates, Inc. have voting power over?

T. Rowe Price Associates, Inc. reports sole voting power over 6,359,951 shares of Guardant Health common stock. It reports no shared voting power in this Schedule 13G/A filing.

How many Guardant Health (GH) shares can T. Rowe Price Associates, Inc. dispose of?

T. Rowe Price Associates, Inc. reports sole dispositive power over 6,514,828 shares of Guardant Health common stock and no shared dispositive power, meaning it alone can direct the disposition of those shares.

What total number of Guardant Health (GH) shares are beneficially owned by T. Rowe Price Associates, Inc.?

T. Rowe Price Associates, Inc. reports beneficial ownership of 6,514,828 GH common shares. This stake represents 4.9% of Guardant Health’s outstanding common stock as disclosed in the Schedule 13G/A amendment.

Does T. Rowe Price Associates, Inc. admit beneficial ownership of Guardant Health (GH) shares in this filing?

No. T. Rowe Price Associates, Inc. expressly denies that this filing should be construed as an admission that it is the beneficial owner of the Guardant Health securities referenced.

When is the ownership information for Guardant Health (GH) in this Schedule 13G/A effective?

The ownership information is stated as of June 30, 2026. As of that date, T. Rowe Price Associates, Inc. reported holding 6,514,828 shares, representing 4.9% of Guardant Health’s common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





40131M109

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Associates, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:08/14/2026